| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
CTPI-2 (CTPI2) is a novel, potent, specific, and third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet.
| ln Vivo |
The specific glycolysis regulator CTPI-2 restricts the metabolic adaptability of cancer stem cells (CSCs). Non-small cell lung cancer (NSCLC) in vivo model tumor growth is inhibited by intraperitoneal administration of CTPI-2 (26 mg/kg) [1]. ?In a prevention study, CTPI-2 (50 mg/kg; intraperitoneal injection; every other day for 12 weeks) entirely avoided weight gain, and in a reversal study, it significantly reduced weight [2]. ?CTPI-2 restores normal glucose tolerance and avoids steatohepatitis. In addition to boosting anti-inflammatory IL-4 and IL-10, CTPI-2 decreases circulating levels of IL-6 and decreases interferon gamma-induced monocyte chemoattractant protein 1 and monokine that draw neutrophils and monocytes. Citrate depots, adipogenesis, and gluconeogenesis pathways are all regulated by CTPI-2 [2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice (HFD-fed mice) [2]
Doses: 50 mg/kg Route of Administration: Via intraperitonealroute on alternate days for 12 weeks Experimental Results: Complete avoidance of weight gain in prevention study, and resulted in significant weight loss regression studies. |
| References |
|
| Molecular Formula |
C13H11N2O6SCL
|
|---|---|
| Molecular Weight |
358.75424
|
| Exact Mass |
355.987
|
| CAS # |
68003-38-3
|
| Related CAS # |
68003-38-3;
|
| PubChem CID |
106350
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.66g/cm3
|
| Boiling Point |
564.8ºC at 760 mmHg
|
| Flash Point |
295.4ºC
|
| Index of Refraction |
1.678
|
| LogP |
4.424
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
558
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NJTHPOSQGFJTDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
|
| Chemical Name |
2-[(4-chloro-3-nitrophenyl)sulfonylamino]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~350.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7875 mL | 13.9373 mL | 27.8746 mL | |
| 5 mM | 0.5575 mL | 2.7875 mL | 5.5749 mL | |
| 10 mM | 0.2787 mL | 1.3937 mL | 2.7875 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
